MCID: PLM035
MIFTS: 46

Pulmonary Eosinophilia malady

Categories: Respiratory diseases, Blood diseases

Aliases & Classifications for Pulmonary Eosinophilia

Aliases & Descriptions for Pulmonary Eosinophilia:

Name: Pulmonary Eosinophilia 12 52 14 69
Asthmatic Pulmonary Eosinophilia 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9498
ICD9CM 35 518.3
MeSH 42 D011657
ICD10 33 J82
UMLS 69 C0034068

Summaries for Pulmonary Eosinophilia

MalaCards based summary : Pulmonary Eosinophilia, also known as asthmatic pulmonary eosinophilia, is related to pulmonary tuberculosis and loeffler syndrome. An important gene associated with Pulmonary Eosinophilia is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Nitric Oxide and Montelukast have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are hematopoietic system and immune system

Related Diseases for Pulmonary Eosinophilia

Diseases related to Pulmonary Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 153)
id Related Disease Score Top Affiliating Genes
1 pulmonary tuberculosis 28.8 CCL11 CCL5 IL13 IL4 IL5 RNASE3
2 loeffler syndrome 11.7
3 eosinophilic pneumonia 11.5
4 chronic eosinophilic pneumonia 11.4
5 idiopathic acute eosinophilic pneumonia 11.2
6 restrictive cardiomyopathy 10.3 IL5 RNASE3
7 peptidic growth factors deficiency 10.3 CCL11 IL5
8 natural killer cell leukemia 10.3 CCL11 IL5
9 brown shrimp allergy 10.3 IL5 RNASE3
10 dahlberg borer newcomer syndrome 10.2 IL13 IL5
11 hidradenitis suppurativa 10.2 CCL11 CCL5
12 vulvar disease 10.2 CCL5 RNASE3
13 papillary squamous carcinoma 10.2 IL4 IL5
14 benign meningioma 10.2 IL5 RNASE3
15 aortic atherosclerosis 10.2 IL13 IL5
16 psychotic disorder 10.2 CCL11 IL4
17 hypersensitivity vasculitis 10.2 IL4 IL5
18 allescheriosis 10.2 IL4 IL5
19 retinal vascular disease 10.2 CCL11 IL4
20 urethral intrinsic sphincter deficiency 10.2 IL4 IL5
21 israeli tick typhus 10.2 CCL5 IL13
22 amelogenesis imperfecta 1j 10.2 EPX RNASE3
23 breast intracanalicular fibroadenoma 10.2 IL4 IL5
24 isthmus cancer 10.2 CCL11 IL4
25 middle lobe syndrome 10.2 CCL17 IL5
26 choledochal cyst 10.2 CSF2 IL5
27 crustacean allergy 10.2 IL13 IL4
28 histoplasmosis retinitis 10.2 IL4 IL5
29 familial renal papillary carcinoma 10.2 CCL11 IL5 RNASE3
30 goat milk allergy 10.2 IL13 IL4
31 monocytic leukemia 10.2 CCL11 IL5 RNASE3
32 osteodysplasty precocious of danks mayne and kozlowski 10.1 CCL5 IL4
33 marasmus 10.1 IL4 IL5 RNASE3
34 appendix carcinoid tumor 10.1 EPX RNASE3
35 lens-induced iridocyclitis 10.1 IL4 IL5 RNASE3
36 multiple epiphyseal dysplasia due to collagen 9 anomaly 10.1 IL4 IL5 RNASE3
37 orbit alveolar rhabdomyosarcoma 10.1 IL4 IL5 RNASE3
38 anterior dislocation of lens 10.1 CCL11 IL4 RNASE3
39 chemical colitis 10.1 EPX RNASE3
40 small intestine lymphoma 10.1 IL5 RNASE3
41 spastic diplegia 10.1 CCL11 IL13 IL5
42 sarcoma 10.1 CSF2 IL4
43 disordered steroidogenesis due to cytochrome p450 oxidoreductase 10.1 CCL11 IL13 IL5
44 hydrops of gallbladder 10.1 CCL5 IL4 IL5
45 asthma 10.1
46 prostate small cell carcinoma 10.1 IL13 IL5
47 hypercementosis 10.1 CCL5 IL13 IL5
48 conjunctival concretion 10.1 CCL11 IL13 IL5
49 smooth muscle tumor 10.1 CCL5 IL13 IL5
50 primary optic atrophy 10.1 CCL5 CSF2

Comorbidity relations with Pulmonary Eosinophilia via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Bronchitis Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Iron Deficiency Anemia Ischemic Heart Disease
Postinflammatory Pulmonary Fibrosis Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Pulmonary Eosinophilia:



Diseases related to Pulmonary Eosinophilia

Symptoms & Phenotypes for Pulmonary Eosinophilia

MGI Mouse Phenotypes related to Pulmonary Eosinophilia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.76 CCL11 CCL17 CCL5 CSF2 EPX IL13
2 immune system MP:0005387 9.56 CCL11 CCL17 CCL5 CSF2 EPX IL13
3 respiratory system MP:0005388 9.02 CCL11 CSF2 IL13 IL4 IL5

Drugs & Therapeutics for Pulmonary Eosinophilia

Drugs for Pulmonary Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
2
Montelukast Approved Phase 4 158966-92-8 5281040
3
Budesonide Approved Phase 4 51333-22-3 63006 5281004
4
Omalizumab Approved, Investigational Phase 4 242138-07-4
5
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
6
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
8 glucocorticoids Phase 4,Phase 3,Phase 2
9 Hormone Antagonists Phase 4,Phase 3,Phase 2
10 Hormones Phase 4,Phase 3,Phase 2
11 Peripheral Nervous System Agents Phase 4,Phase 2
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
13 Anti-Allergic Agents Phase 4,Phase 2
14 Anti-Asthmatic Agents Phase 4,Phase 2
15 Immunoglobulins Phase 4,Phase 3,Phase 2
16 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2
17 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
18 Leukotriene Antagonists Phase 4
19 Respiratory System Agents Phase 4,Phase 2
20 Antibodies Phase 4,Phase 3,Phase 2
21 Autonomic Agents Phase 4,Phase 2
22 Bronchodilator Agents Phase 4,Phase 2
23 Prednisolone acetate Phase 4,Phase 3
24
Salmeterol xinafoate Phase 4,Phase 2 94749-08-3 56801
25
Fluticasone Phase 4,Phase 2 90566-53-3, 80474-14-2 62924 22833648
26 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4,Phase 2
27 Adrenergic Agents Phase 4,Phase 2
28 Adrenergic Agonists Phase 4,Phase 2
29 Gastrointestinal Agents Phase 4
30 Neuroprotective Agents Phase 4
31 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2
32 Adrenergic beta-Agonists Phase 4,Phase 2
33 Neurotransmitter Agents Phase 4,Phase 2
34 Albuterol Phase 4,Phase 2
35 Tocolytic Agents Phase 4,Phase 2
36 Dermatologic Agents Phase 4,Phase 2
37 Immunoglobulin E Phase 4
38 Prednisolone hemisuccinate Phase 4,Phase 3
39 Prednisolone phosphate Phase 4,Phase 3
40 Protective Agents Phase 4,Phase 2,Phase 1
41 Antiemetics Phase 4
42 Methylprednisolone acetate Phase 4,Phase 3
43 Methylprednisolone Hemisuccinate Phase 4,Phase 3
44 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
45 Antioxidants Phase 4,Phase 2,Phase 1
46 Fluorodeoxyglucose F18 Phase 4
47 Radiopharmaceuticals Phase 4
48 Tiotropium Bromide Phase 4 136310-93-5
49 Muscarinic Antagonists Phase 4
50 Cholinergic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 67)
id Name Status NCT ID Phase
1 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4
2 Efficacy and Safety of add-on Montelukast to Inhaled Budesonide in the Treatment of Nonasthmatic Eosinophilic Bronchitis Unknown status NCT01121016 Phase 4
3 The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4
4 Small Particle Steroids in Refractory Asthma Completed NCT01171365 Phase 4
5 Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists Completed NCT00670930 Phase 4
6 An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation Recruiting NCT02937168 Phase 4
7 The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma Recruiting NCT03034005 Phase 4
8 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Active, not recruiting NCT02654145 Phase 4
9 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Active, not recruiting NCT02546349 Phase 4
10 Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations Unknown status NCT01520051 Phase 3
11 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed NCT01285323 Phase 3
12 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3
13 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3
14 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3
15 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3
16 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3
17 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Recruiting NCT02555371 Phase 3
18 A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Recruiting NCT03052725 Phase 3
19 Study of Mepolizumab Autoinjector in Asthmatics Recruiting NCT03099096 Phase 3
20 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Recruiting NCT02836496 Phase 3
21 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Recruiting NCT02563067 Phase 3
22 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Recruiting NCT02555683 Phase 3
23 Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Active, not recruiting NCT02594332 Phase 3
24 Study of Mepolizumab Safety Syringe in Asthmatics Active, not recruiting NCT03021304 Phase 3
25 A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Active, not recruiting NCT02135692 Phase 3
26 Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Enrolling by invitation NCT02559791 Phase 2, Phase 3
27 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Terminated NCT01290887 Phase 3
28 A Phase IIa Study of KHK4563 Completed NCT01412736 Phase 2
29 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed NCT01312961 Phase 2
30 A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01227278 Phase 2
31 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2
32 Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Completed NCT00086658 Phase 2
33 OC000459 Bronchial Allergen Challenge Completed NCT01056692 Phase 2
34 Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects Completed NCT01057927 Phase 2
35 Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma Completed NCT01545726 Phase 2
36 Oral GW766944 (Oral CCR3 Antagonist) Completed NCT01160224 Phase 2
37 The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563) Completed NCT00292877 Phase 2
38 A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study) Completed NCT00535028 Phase 2
39 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2
40 Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Recruiting NCT02560610 Phase 2
41 Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome Recruiting NCT02130882 Phase 2
42 Effect of OC459 on the Response to Rhinovirus Challenge in Asthma Recruiting NCT02660489 Phase 2
43 Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children Active, not recruiting NCT02377427 Phase 2
44 Investigation of Lung Ventilation Inhomogeneity in Pediatric Asthma Active, not recruiting NCT01095354 Phase 2
45 Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome Active, not recruiting NCT02101138 Phase 2
46 Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements Completed NCT00466596 Phase 1
47 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1
48 Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma Recruiting NCT03137199 Phase 1
49 Sirolimus for Eosinophil-Associated Gastrointestinal Disorders Terminated NCT01814059 Phase 1
50 Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial Pneumonia Unknown status NCT01152424

Search NIH Clinical Center for Pulmonary Eosinophilia

Genetic Tests for Pulmonary Eosinophilia

Anatomical Context for Pulmonary Eosinophilia

MalaCards organs/tissues related to Pulmonary Eosinophilia:

39
Lung, T Cells, Testes, Heart, Bone, Bone Marrow, Breast

Publications for Pulmonary Eosinophilia

Articles related to Pulmonary Eosinophilia:

(show top 50) (show all 288)
id Title Authors Year
1
Pulmonary Eosinophilia From Inhaled Colistin. ( 28065254 )
2017
2
Concurrent sensitization to Aspergillus Fumigatus in tropical pulmonary eosinophilia. ( 27374215 )
2016
3
Pulmonary eosinophilia associated to treatment with natalizumab. ( 27512514 )
2016
4
Acetaminophen Use: An Unusual Cause of Drug-Induced Pulmonary Eosinophilia. ( 27445539 )
2016
5
A rare presentation of hydropneumothorax in tropical pulmonary eosinophilia: cavitation and pneumonic consolidation in a child. ( 26376823 )
2015
6
An Unusual Case of Foreign Body Aspiration Masquerading as Pulmonary Eosinophilia. ( 26266154 )
2015
7
Natural helper cells contribute to pulmonary eosinophilia by producing IL-13 via IL-33/ST2 pathway in a murine model of respiratory syncytial virus infection. ( 26044350 )
2015
8
Host lung immunity is severely compromised during tropical pulmonary eosinophilia: role of lung eosinophils and macrophages. ( 26489428 )
2015
9
Simple pulmonary eosinophilia associated with clozapine treatment. ( 25514065 )
2015
10
Simple pulmonary eosinophilia found on follow-up computed tomography of oncologic patients. ( 25082475 )
2014
11
Pulmonary eosinophilia caused by testosterone cypionate. ( 23998379 )
2013
12
A rare case of ethambutol induced pulmonary eosinophilia. ( 24250213 )
2013
13
Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. ( 23926350 )
2013
14
Tropical pulmonary eosinophilia--a review. ( 24135173 )
2013
15
Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. ( 22331917 )
2012
16
Interleukin-17 drives pulmonary eosinophilia following repeated exposure to Aspergillus fumigatus conidia. ( 22252873 )
2012
17
FICZ, a tryptophan photoproduct, suppresses pulmonary eosinophilia and Th2-type cytokine production in a mouse model of ovalbumin-induced allergic asthma. ( 22561122 )
2012
18
Tropical pulmonary eosinophilia misdiagnosed as miliary tuberculosis: a case report and literature review. ( 22172479 )
2012
19
Regulator of calcineurin 1 (Rcan1) is required for the development of pulmonary eosinophilia in allergic inflammation in mice. ( 21741935 )
2011
20
Acquired alpha 1-antitrypsin deficiency in tropical pulmonary eosinophilia. ( 21808138 )
2011
21
A mouse model of airway disease: oncostatin M-induced pulmonary eosinophilia, goblet cell hyperplasia, and airway hyperresponsiveness are STAT6 dependent, and interstitial pulmonary fibrosis is STAT6 independent. ( 21160052 )
2011
22
Role of oxidants in interstitial lung diseases: pneumoconioses, constrictive bronchiolitis, and chronic tropical pulmonary eosinophilia. ( 22131646 )
2011
23
Chlorogenic acid suppresses pulmonary eosinophilia, IgE production, and Th2-type cytokine production in an ovalbumin-induced allergic asthma: activation of STAT-6 and JNK is inhibited by chlorogenic acid. ( 20637839 )
2010
24
Levels of circulating IL-33 and eosinophil cationic protein in patients with hypereosinophilia or pulmonary eosinophilia. ( 20719375 )
2010
25
Serum C3d levels in tropical pulmonary eosinophilia. ( 20424307 )
2010
26
Oral tolerance inhibits pulmonary eosinophilia in a cockroach allergen induced model of asthma: a randomized laboratory study. ( 21092270 )
2010
27
Enhancement of ovalbumin-induced pulmonary eosinophilia by intranasal administration of alpha1-proteinase inhibitor type 2 antisense oligonucleotides. ( 19111575 )
2009
28
Pulmonary eosinophilia. ( 19618037 )
2009
29
Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. ( 19594395 )
2009
30
Clinical alterations and mRNA levels of IL-4 and IL-5 in bronchoalveolar cells of horses with transient pulmonary eosinophilia. ( 17996260 )
2008
31
Pulmonary eosinophilia correlates with allergen deposition to the lower respiratory tract in a mouse model of asthma. ( 18537985 )
2008
32
Transient pulmonary eosinophilia incidentally found on low-dose computed tomography: findings in 40 individuals. ( 18303297 )
2008
33
Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. ( 18519743 )
2008
34
Pulmonary eosinophilia. ( 18197481 )
2008
35
The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. ( 19017987 )
2008
36
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. ( 18242596 )
2008
37
Tropical pulmonary eosinophilia in a patient undergoing open heart surgery. ( 18285744 )
2008
38
Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. ( 18094193 )
2008
39
A carbohydrate fraction, AIP1 from Artemisia iwayomogi suppresses pulmonary eosinophilia and Th2-type cytokine production in an ovalbumin-induced allergic asthma. Down-regulation of TNF-alpha expression in the lung. ( 18068107 )
2008
40
Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management. ( 17940489 )
2007
41
C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. ( 17079327 )
2007
42
A critical role for Pin1 in allergic pulmonary eosinophilia in rats. ( 17720236 )
2007
43
Eosinophilic pustular folliculitis associated with pulmonary eosinophilia. ( 17714146 )
2007
44
Tropical pulmonary eosinophilia: a rare cause of cough in immigrants to Australia. ( 17908009 )
2007
45
Elevated levels of fragmented laminin-5 gamma2-chain in bronchoalveolar lavage fluid from dogs with pulmonary eosinophilia. ( 16624727 )
2006
46
Death receptor-6 regulates the development of pulmonary eosinophilia and airway inflammation in a mouse model of asthma. ( 16730379 )
2006
47
Parasitic pulmonary eosinophilia. ( 16612768 )
2006
48
Simple pulmonary eosinophilia evaluated by means of FDG PET: the findings of 14 cases. ( 16374077 )
2005
49
Tropical pulmonary eosinophilia. ( 15712096 )
2005
50
A rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice. ( 15607129 )
2005

Variations for Pulmonary Eosinophilia

Expression for Pulmonary Eosinophilia

Search GEO for disease gene expression data for Pulmonary Eosinophilia.

Pathways for Pulmonary Eosinophilia

Pathways related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 32)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 CCL11 CCL5 CSF2 EPX IL13 IL4
2
Show member pathways
13.65 CCL11 CCL17 CCL5 CCL7 CSF2 IL13
3
Show member pathways
13.46 CCL11 CCL17 CCL5 CCL7 CSF2 IL13
4
Show member pathways
13.36 CCL11 CCL17 CCL5 CCL7 IL13 IL4
5
Show member pathways
13.19 CCL11 CCL5 CSF2 IL13 IL4 IL5
6
Show member pathways
13.18 CCL11 CCL17 CCL5 CCL7 CSF2 IL13
7
Show member pathways
13.03 CCL11 CCL17 CCL5 CCL7 CSF2 IL13
8
Show member pathways
12.69 CCL11 CCL17 CCL5 CCL7
9
Show member pathways
12.69 CCL11 EPX IL13 IL4 IL5 RNASE3
10
Show member pathways
12.45 CSF2 IL13 IL4 IL5
11
Show member pathways
12.24 CSF2 IL4 IL5
12
Show member pathways
12.17 CCL11 CCL5 CCL7
13
Show member pathways
12.11 CSF2 IL13 IL4 IL5
14
Show member pathways
12.03 CCL11 CCL17 CCL7 CSF2 IL13 IL4
15
Show member pathways
12.02 IL13 IL4 IL5
16
Show member pathways
11.93 CCL11 CCL17 CCL5 CCL7
17 11.87 CSF2 IL4 IL5
18 11.86 CCL11 IL13 IL4
19 11.77 CSF2 IL4 IL5
20 11.71 CSF2 IL13 IL4 IL5
21 11.68 IL13 IL4 IL5
22
Show member pathways
11.65 CSF2 IL4 IL5
23 11.56 CCL11 CCL17 IL4 IL5
24 11.4 CCL5 CSF2 IL13 IL4
25 11.33 CCL11 CCL17 IL13 IL4 IL5
26 11.24 IL13 IL4 IL5
27 11.23 CCL11 CCL5 CSF2 IL13 IL4 IL5
28 11.17 IL4 IL5
29 11.14 IL13 IL4 IL5
30 11.1 CSF2 IL13 IL4 IL5
31 10.86 IL13 IL4 IL5
32 10.46 CCL11 CCL17 CCL5 CCL7 CSF2 IL13

GO Terms for Pulmonary Eosinophilia

Cellular components related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CCL11 CCL17 CCL5 CCL7 CSF2 EPX
2 extracellular space GO:0005615 9.32 CCL11 CCL17 CCL5 CCL7 CSF2 EPX

Biological processes related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of GTPase activity GO:0043547 9.95 CCL11 CCL17 CCL5 CCL7 CSF2 IL5
2 cell-cell signaling GO:0007267 9.88 CCL17 CCL5 CCL7 IL13
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.84 CCL11 CCL17 CCL5 CCL7
4 positive regulation of cell migration GO:0030335 9.82 CCL11 CCL5 CCL7
5 cellular response to tumor necrosis factor GO:0071356 9.8 CCL11 CCL17 CCL5 CCL7
6 cellular calcium ion homeostasis GO:0006874 9.77 CCL11 CCL5 CCL7
7 cellular response to interleukin-1 GO:0071347 9.76 CCL11 CCL17 CCL5 CCL7
8 chemokine-mediated signaling pathway GO:0070098 9.73 CCL11 CCL17 CCL5 CCL7
9 inflammatory response GO:0006954 9.73 CCL11 CCL17 CCL5 CCL7 IL13 IL5
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 CCL5 CSF2 IL4
11 neutrophil chemotaxis GO:0030593 9.71 CCL11 CCL17 CCL5 CCL7
12 positive regulation of B cell proliferation GO:0030890 9.69 IL13 IL4 IL5
13 cellular response to interferon-gamma GO:0071346 9.67 CCL11 CCL17 CCL5 CCL7
14 lymphocyte chemotaxis GO:0048247 9.65 CCL11 CCL17
15 negative regulation of endothelial cell apoptotic process GO:2000352 9.65 IL13 IL4
16 innate immune response in mucosa GO:0002227 9.64 IL4 RNASE3
17 positive regulation of JAK-STAT cascade GO:0046427 9.63 CCL5 IL5
18 myeloid dendritic cell differentiation GO:0043011 9.63 CSF2 IL4
19 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.62 CSF2 IL4
20 microglial cell activation GO:0001774 9.62 IL13 IL4
21 positive regulation of podosome assembly GO:0071803 9.61 CSF2 IL5
22 dendritic cell differentiation GO:0097028 9.61 CSF2 IL4
23 positive regulation of mast cell degranulation GO:0043306 9.59 IL13 IL4
24 positive regulation of immunoglobulin production GO:0002639 9.58 IL13 IL4
25 positive regulation of natural killer cell chemotaxis GO:2000503 9.57 CCL5 CCL7
26 regulation of proton transport GO:0010155 9.56 IL13 IL4
27 chemotaxis GO:0006935 9.55 CCL11 CCL17 CCL5 CCL7 IL4
28 negative regulation of complement-dependent cytotoxicity GO:1903660 9.52 IL13 IL4
29 eosinophil chemotaxis GO:0048245 9.5 CCL11 CCL5 CCL7
30 monocyte chemotaxis GO:0002548 9.26 CCL11 CCL17 CCL5 CCL7
31 immune response GO:0006955 9.23 CCL11 CCL17 CCL5 CCL7 CSF2 IL13

Molecular functions related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.5 CSF2 IL4 IL5
2 cytokine receptor binding GO:0005126 9.4 IL13 IL4
3 CCR chemokine receptor binding GO:0048020 9.37 CCL11 CCL17
4 CCR1 chemokine receptor binding GO:0031726 9.26 CCL5 CCL7
5 chemokine activity GO:0008009 9.26 CCL11 CCL17 CCL5 CCL7
6 cytokine activity GO:0005125 9.23 CCL11 CCL17 CCL5 CCL7 CSF2 IL13
7 CCR4 chemokine receptor binding GO:0031729 9.16 CCL17 CCL5

Sources for Pulmonary Eosinophilia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....